We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App





Johnson & Johnson in Talks with EU for Sale of COVID-19 Vaccine Under Development

By HospiMedica International staff writers
Posted on 19 Jun 2020
Johnson & Johnson (New Brunswick, NJ, USA) is in advanced discussions with the European Commission to reserve or make an up-front purchase of its COVID-19 vaccine under development, according to a report by Reuters.

The European Union executive has been mandated by the 27 EU national governments to use an emergency fund of more than USD 2.3 billion to enter into deals with up to six vaccine producers. More...
Last week, Germany, France, Italy and the Netherlands had announced that that they had acquired 400 million potential COVID-19 vaccine doses from AstraZeneca which is collaborating with Oxford University to develop the vaccine. AstraZeneca has also entered into an agreement to supply potential COVID-19 vaccine doses to the US.

Now, a top health official from an EU member state has told Reuters that the Commission’s deal was “in the pipeline” for Johnson & Johnson’s experimental COVID-19 vaccine which is set to enter human trials in July. There was no mention of whether the EU was looking to make an advance purchase of the vaccine currently being tested or buy it. Johnson & Johnson responded to Reuters’ queries by stating that the company was in discussions with several governments and organizations globally even as it is developing a COVID-19 vaccine.

Related Links:
Johnson & Johnson


Gold Member
Neonatal Heel Incision Device
Tenderfoot
Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
X-Ray Generator
Advantage Plus Generators
Surgical Dressing
ALLEVYN Ag+ SURGICAL
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Critical Care

view channel
Image: Reusable catheter patients used 35 percent fewer antibiotics compared to their single-use only counterparts. (Photo courtesy of the University of Southampton)

Reusable Intermittent Catheters Reduce Antibiotic Use Without Increasing Urinary Tract Infections

Intermittent self-catheterization, used to empty the bladder several times a day, can leave patients vulnerable to recurrent urinary tract infections and repeated antibiotic use. Reliance on single-use... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.